Federal Prosecutors Reject $1 Billion Risperdal Settlement Offer
Pushing for a larger settlement, federal prosecutors rejected Johnson & Johnson’s $1 billion settlement offer for allegedly improperly marketing the antipsychotic drug Risperdal.
Johnson & Johnson allegedly marketed the drug—which received approval by the Food and Drug Administration (FDA) in 1993 for the treatment of psychotic disorders including schizophrenia—for unapproved uses. A March 12 Bloomberg article on the case said federal prosecutors are seeking at least $800 million more.
The federal government launched an investigation into Johnson & Johnson’s sales practices for Risperdal in 2004. The pharmaceutical company is accused of marketing Risperdal for bipolar disorder, dementia, eating disorders, obsessive-compulsive disorder, anxiety disorders and other uses not approved by the FDA; it was later approved for treatment of bipolar disorder.
Risperdal was also allegedly marketed to nursing homes for residents with dementia-related psychosis, and the drug earned a black box warning because of an increased risk of potentially deadly side-effects in elderly patients.
Johnson & Johnson is also facing similar Risperdal lawsuits from numerous states. In January, the company and Texas agreed to a nearly $160 million settlement over accusations that Johnson & Johnson improperly sold the drug to residents on Medicaid, including children with attention deficit hyperactivity disorder.
If you experienced side-effects from taking Risperdal or a family member died due to Risperdal-related complications, please contact PersonalInjury.com for a free case evaluation and to locate an experienced dangerous pharmaceutical attorney near you.